Patents by Inventor Steen Lisby

Steen Lisby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74
    Publication number: 20220323582
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: October 15, 2021
    Publication date: October 13, 2022
    Inventors: Sandra VERPLOEGEN, Marije OVERDIJK, Riemke VAN DIJKHUIZEN, Willem Karel BLEEKER, Patrick VAN BERKEL, Paul PARREN, Steen LISBY
  • DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES
    Publication number: 20220265844
    Abstract: Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.
    Type: Application
    Filed: December 10, 2021
    Publication date: August 25, 2022
    Inventors: Steen LISBY, Nancy Cherry WHITING
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20210395384
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: March 10, 2021
    Publication date: December 23, 2021
    Inventors: David SATJIN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20210177987
    Abstract: The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).
    Type: Application
    Filed: November 1, 2018
    Publication date: June 17, 2021
    Inventors: Reshma Abdulla RANGWALA, Steen LISBY
  • COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
    Publication number: 20200114000
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: September 12, 2019
    Publication date: April 16, 2020
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Yvo GRAUS, Judith OPRINS, Michel DE WEERS, Martine VAN VUGT, Ole BAADSGAARD, Steen LISBY
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20190315880
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: March 28, 2019
    Publication date: October 17, 2019
    Inventors: David SATIJN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • NEW DOSAGE REGIMENS FOR ANTIBODY DRUG CONJUGATES BASED ON ANTI-AXL ANTIBODIES
    Publication number: 20190233522
    Abstract: An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/kg to about 2.0 mg/kg of the ADC once a week for three consecutive weeks followed by a one week resting period without any administration of the ADC so that each cycle time is 28 days including the resting period.
    Type: Application
    Filed: July 7, 2017
    Publication date: August 1, 2019
    Inventors: Ulf FORSSMANN, Steen LISBY, Nedjad LOSIC
  • DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES
    Publication number: 20190030178
    Abstract: Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.
    Type: Application
    Filed: September 9, 2016
    Publication date: January 31, 2019
    Applicant: Genmab A/S
    Inventors: Steen LISBY, Nancy Cherry WHITING
  • HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74
    Publication number: 20170173151
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: December 1, 2016
    Publication date: June 22, 2017
    Inventors: Sandra VERPLOEGEN, Marije OVERDIJK, Riemke van DIJKHUIZEN, Willem Karel BLEEKER, Patrick VAN BERKEL, Paul PARREN, Steen LISBY
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20170136130
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: September 27, 2016
    Publication date: May 18, 2017
    Inventors: David SATIJN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • Human antibodies and antibody-drug conjugates against CD74
    Patent number: 9540433
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: January 10, 2017
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
  • Human antibody drug conjugates against tissue factor
    Patent number: 9492565
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: November 15, 2016
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Method of treating rash in patients undergoing anti-EGFR therapy
    Patent number: 9428582
    Abstract: The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 30, 2016
    Assignee: GENMAB A/S
    Inventors: Klaus Edvardsen, Steen Lisby, Ole Baadsgaard
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20160067349
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: September 15, 2015
    Publication date: March 10, 2016
    Inventors: David SATIJN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • Human antibody drug conjugates against tissue factor
    Patent number: 9168314
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 27, 2015
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
    Publication number: 20150231235
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: December 10, 2014
    Publication date: August 20, 2015
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Yvo GRAUS, Judith OPRINS, Michel DE WEERS, Martine VAN VUGT, Ole BAADSGAARD, D.M.Sc., Steen LISBY
  • Combination treatment of CD38-expressing tumors
    Patent number: 9040050
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: May 26, 2015
    Assignee: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74
    Publication number: 20140030273
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: February 1, 2012
    Publication date: January 30, 2014
    Applicant: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20130101608
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: June 15, 2011
    Publication date: April 25, 2013
    Applicant: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • CD20 Binding Molecules for the Treatment of Copd
    Publication number: 20130004480
    Abstract: Use of CD20 binding molecules, such as anti-CD20 antibodies, for the treatment of chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: July 4, 2007
    Publication date: January 3, 2013
    Inventors: Paul Parren, Steen Lisby, Ole Baadsgaard